A cross-border life science investment firm focuses on investments in therapeutics, medical devices, diagnostics, and life science tools. The firm invests from its latest fund of almost $1B and currently manages over $2B AUM. In addition to investing in companies in USA, Europe, and Asia, the firm is actively involved in supporting their portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-$30 MM USD.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products, but is open to promising, earlier stage opportunities with strong clinical data. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A biotechnology company is dedicated to the development of genetic detection platforms incorporated with microarrays, Next Generation Sequencing (NGS) and big data analysis for health informatics. The core services of the firm lie upon five areas within reproductive medicine (prenatal/postnatal testing), population medicine, medical oncology, liver DNA methylation test, and scientific research services.

The firm is looking for co-development and in-licensing opportunities that are a fit for their current pipelines/business areas and is open to equity investments on a case-by-case basis. For equity investments, the check size is usually under $10M, ranging between $2M – $10M. The firm is interested in opportunities globally.

The firm looks for assets that align with their current pipelines and core services. Interested areas include in-vitro diagnostics, oncology therapeutics, reproductive and women’s health related technologies. The firm is open to working with companies in different phases of development.There are no specific requirements for the company and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with initial check sizes between 1 – 3 million USD. The firm prefers to lead/co-lead the financing rounds but is open to co-investing. The firm is focused on companies located in North America and Israel.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, The firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture subsidiary of a pharmaceutical company is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment.

The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Kendall Sq. Cambridge, MA, November 30th, 2023 — Life Science Nation (LSN), the visionary force behind the globally acclaimed Redefining Early Stage Investments (RESI) Conference Series, is thrilled to announce a strategic collaboration with Biocat, headquartered in Barcelona, Catalonia, Spain, and Biotechgate, Zurich, Switzerland. Biocat, a catalyzing organization dedicated to transforming the BioRegion of Catalonia into a premier life sciences and health innovation ecosystem in Europe, and Biotechgate, a pioneer in curating and marketing a global business development database tailored for the life science industry, join forces with LSN to bring the RESI global matching platform back to Europe.

The RESI Conference Series has been instrumental in connecting healthcare startups with capital investors, co-development partners, and licensing opportunities worldwide. LSN has a track record of assisting over 400 startups in raising over $5 billion through its investor database, entrepreneurial education, and RESI international partnering events. The LSN partner network, comprising ten categories of investors and licensing partners, actively seeks early-stage innovations in drugs, devices, diagnostics, and digital health for investment portfolio and product pipeline development.

The Power of RESI Partnering

The RESI Partnering platform is a dynamic tool designed to match attendees based on sector, indication, and development phase and is central to the RESI Conference Series. This innovative approach eliminates most ill-fitting meetings, ensuring startups engage with the right investors and licensing partners who align with their specific needs and goals. RESI partnering events run five times annually at life science centers worldwide. They facilitate fundraising CEOs and scientist-entrepreneurs to get out of their local region and into the international market, dramatically increasing the number of potential partners in their pipeline. Fundraising is a numbers game; a startup cannot succeed with one or two conferences yearly. LSN’s startups seek seed funding up to 2M, Series A, 2M-10M, and Series B, 10M-50M. As part of their global partnering campaign initiative, startup companies leverage RESI as a strategic launchpad to meet national and international investors and licensing partners.

“Biocat is unique in Europe because they get it; they understand that shining an international light on their startups and getting them into capital and licensing arrangements early builds the ecosystem’s future,” says Dennis Ford, CEO of Life Science Nation.

Robert Fabregat, CEO of Biocat, said, “LSN has developed a buy-side network that will bring tens of millions of Euros into the BioRegion. Biocat is confident that our rich life science technology ecosystem will capture the attention of global investors and licensing partners and enhance BioRegion’s global footprint.”

Patrik Frei, CEO of Biotechgate, stated, “The Catalan BioRegion, like many others in the European market, is not getting enough of the early-stage investor attention they deserve. Now, startups can attend RESI Europe Barcelona, meet LSN’s global partners, and plug into international RESI events in and outside Europe.”

About RESI Conference Series

RESI is a well-established go-to partnering event series for international scientist-entrepreneurs and fundraising CEOs. It offers a dynamic interactive format featuring one day of face-to-face meetings and two days of global virtual partnering. The RESI Conference Series spans North America, Europe, and Asia, receiving support from governmental agencies, regional international tech hubs, incubators, and accelerators. The 2024 RESI partnering events are scheduled as follows: RESI JPM in San Francisco on January 9th, RESI South Atlanta on March 25th, RESI Europe Barcelona on June 17th, RESI Boston on September 25th, and RESI Asia (location and partner TBD) in November.

About Life Science Nation (LSN)

Life Science Nation (LSN) created the globally recognized Redefining Early Stage Investments (RESI) Conference Series. LSN’s mission is to connect early-stage life science companies with investors and strategic partners, ultimately fostering innovation and driving advancements in the life sciences industry.

About Biocat

Biocat is a strategic stakeholder and catalyst for promoting, transforming and projecting the Catalan life sciences and health innovation ecosystem, known as the BioRegion of Catalonia. It was established in 2006 as a public-private foundation at the behest of the Government of Catalonia and the Barcelona City Council to identify the needs of the BioRegion and implement a strategy and action plan to maximize the economic and social impact of the sector.

About Biotechgate

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Startups affiliated with a tech hub such an incubator, accelerator, university, non-profit, or government agency are eligible for up to $600 off tickets to RESI JPM, January 9 – 11th, in San Francisco. To get access to a unique discount code, tech hubs or startups affiliated with tech hubs must reach out to Erika Wu at e.wu@lifesciencenation.com 

Tech hubs are also eligible to save 50% off all sponsorship levels at RESI. This is a great opportunity to showcase your startups’ technologies, host a workshop, be featured in LSN’s Next Phase and Tech Hub newsletters, and sell services at an exhibition booth. 

Don’t miss your chance to get access to: 

1. Networking Opportunities  
2. Access to New Technologies  
3. Deal Flow Generation  
4. Early Market Trends and Insights  
5. Investor Engagement  
6. Brand Visibility  
7. Learning and Education from LSN staff and sponsor 
   
   Tech hubs currently registered for RESI JPM 2024 – Sign Up Here: 

RESI JPM 2024 will occur via a hybrid format, with January 9th being in-person at the Marine’s Memorial Hotel in San Francisco, and the 10th and 11th with virtual partnering only. We are expecting 500+ early-stage life science investors and 500+ startups at the upcoming RESI. Check out who’s currently registered. 

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the dynamic, highly competitive life science arena, a startup company must have its story straight and act together. Understanding that effective communication is the crux of a successful investor and licensing partner campaign. Life science startup companies face the unique challenge of distilling complex ideas into digestible messages for their target audience. In this context, a clear and concise tagline and elevator pitch seamlessly integrated into the one-page data sheet, two-page executive summary, and 10-12-page pitch deck cannot be underestimated. The tagline and elevator pitch you develop for your startup are a potent tool, serving as the linchpin for all your present and future marketing endeavors. The tagline and elevator pitch anchor all your branding and messaging. These two entities are not slogans, they should be viewed in the context that if the right person read them, they would want to have a meeting with you.

LSN Has Developed a Process for the Continuity of Messaging

Life science startups often deal with intricate scientific concepts and advanced technologies. Communicating these complexities to a target audience, including investors, potential collaborators, and licensing partners, requires a delicate balance. A concise tagline is a beacon of clarity, distilling the company’s core purpose and value proposition into a few impactful words. This clarity is essential for effective communication and builds trust and credibility. A good tagline is hard to craft but easy to identify, requiring multiple iterations. Companies will frequently end on a tagline that is partway there, not realizing the difference that more work can make. This is the difference between a tagline such as ‘novel robotic platform to treat cancer’ and ‘Advancing Localized Cancer Interventions with Self-driving Robotic Platform’ – one tagline seems to provide a good amount of detail, while the other is clearly much more detailed but still concise. A well-crafted tagline remains an invaluable asset in the arsenal of marketing materials for startups striving to make a lasting impact.

Life Science Nation announced a Tagline Competition Contest. The top three taglines to receive complimentary registrations to our upcoming partnering conference, RESI JPM in San Francisco at the Marine’s Memorial Club & Hotel on January 9. The staff at LSN evaluated each submission based on clarity, level of detail, and conciseness when considering the top three. Thank you to the companies that applied. LSN evaluated close to 100 submissions. The winners are:

Tagline Competition Contest Winners
	Flexperc Medical
	Advancing Localized Cancer Interventions with Self-driving Robotic Platform
	Nesa Medtech
	Transform women’s health by developing a scarless, image-guided surgical solution to treat uterine fibroids.
	Inherent Biosciences
	Pioneering Epigenetic Diagnostics in Reproductive Health

Congratulations to the winners! We look forward to seeing you at RESI JPM!